Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease

Francesca Palone; Roberta Vitali; Salvatore Cucchiara; Maria Pierdomenico; Anna Negroni; Marina Aloi; Federica Nuti; Carla Felice; Alessandro Armuzzi; Laura Stronati

doi:10.1097/MIB.0000000000000113

Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease

Francesca Palone, Roberta Vitali, Salvatore Cucchiara, Maria Pierdomenico, Anna Negroni, Marina Aloi, Federica Nuti, Carla Felice, Alessandro Armuzzi, Laura Stronati

Università Cattolica del Sacro Cuore

Risultato della ricerca: Contributo in rivista › Articolo in rivista

43 Citazioni (Scopus)

Abstract

Noninvasive biomarkers of high- and low-grade intestinal inflammation and of mucosal healing (MH) in patients with inflammatory bowel disease are currently lacking. We have recently shown that fecal high mobility group box 1 (HMGB1) protein is a novel biomarker of gut inflammation. We aimed at investigating in a mouse model if HMGB1 was able to foresee both a clinically evident and a subclinical gut inflammation and if its normalization indicated MH. We also aimed at confirming the results in patients with Crohn's disease (CD) and ulcerative colitis.

Lingua originale	English
pagine (da-a)	1448-1457
Numero di pagine	10
Rivista	Inflammatory Bowel Diseases
Volume	20
DOI	https://doi.org/10.1097/MIB.0000000000000113
Stato di pubblicazione	Pubblicato - 2014

Keywords

biomarker
inflammatory bowel disease

Accesso al documento

10.1097/MIB.0000000000000113

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{676af09686c64aa9be48dfdd72e8e8a9,

title = "Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease",

abstract = "Noninvasive biomarkers of high- and low-grade intestinal inflammation and of mucosal healing (MH) in patients with inflammatory bowel disease are currently lacking. We have recently shown that fecal high mobility group box 1 (HMGB1) protein is a novel biomarker of gut inflammation. We aimed at investigating in a mouse model if HMGB1 was able to foresee both a clinically evident and a subclinical gut inflammation and if its normalization indicated MH. We also aimed at confirming the results in patients with Crohn's disease (CD) and ulcerative colitis.",

keywords = "biomarker, inflammatory bowel disease, biomarker, inflammatory bowel disease",

author = "Francesca Palone and Roberta Vitali and Salvatore Cucchiara and Maria Pierdomenico and Anna Negroni and Marina Aloi and Federica Nuti and Carla Felice and Alessandro Armuzzi and Laura Stronati",

year = "2014",

doi = "10.1097/MIB.0000000000000113",

language = "English",

volume = "20",

pages = "1448--1457",

journal = "Inflammatory Bowel Diseases",

issn = "1536-4844",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease

AU - Palone, Francesca

AU - Vitali, Roberta

AU - Cucchiara, Salvatore

AU - Pierdomenico, Maria

AU - Negroni, Anna

AU - Aloi, Marina

AU - Nuti, Federica

AU - Felice, Carla

AU - Armuzzi, Alessandro

AU - Stronati, Laura

PY - 2014

Y1 - 2014

N2 - Noninvasive biomarkers of high- and low-grade intestinal inflammation and of mucosal healing (MH) in patients with inflammatory bowel disease are currently lacking. We have recently shown that fecal high mobility group box 1 (HMGB1) protein is a novel biomarker of gut inflammation. We aimed at investigating in a mouse model if HMGB1 was able to foresee both a clinically evident and a subclinical gut inflammation and if its normalization indicated MH. We also aimed at confirming the results in patients with Crohn's disease (CD) and ulcerative colitis.

AB - Noninvasive biomarkers of high- and low-grade intestinal inflammation and of mucosal healing (MH) in patients with inflammatory bowel disease are currently lacking. We have recently shown that fecal high mobility group box 1 (HMGB1) protein is a novel biomarker of gut inflammation. We aimed at investigating in a mouse model if HMGB1 was able to foresee both a clinically evident and a subclinical gut inflammation and if its normalization indicated MH. We also aimed at confirming the results in patients with Crohn's disease (CD) and ulcerative colitis.

KW - biomarker

KW - inflammatory bowel disease

KW - biomarker

KW - inflammatory bowel disease

UR - http://hdl.handle.net/10807/64540

U2 - 10.1097/MIB.0000000000000113

DO - 10.1097/MIB.0000000000000113

M3 - Article

SN - 1536-4844

VL - 20

SP - 1448

EP - 1457

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

ER -

Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo